The General Hospital Corporation;UTI Limited Partnership
发明人:
Pedro Santamaria,Anna Moore
申请号：
US15610550
公开号：
US20170333540A1
申请日:
2017.05.31
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
